天星医疗(01609)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01609 天星医疗

交易中 09-08 14:30:30

121.600

+1.600

+1.33%

最高127.000	最低115.000	成交量17.85万
今开127.000	昨收120.000	日振幅10.00%
总市值66.67亿	流通市值66.67亿	总股本5,483万
成交额2,121万	换手率0.33%	流通股本5,483万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01609","market":"HK","secType":"STK","nameCN":"天星医疗","latestPrice":121.6,"timestamp":1788849004629,"preClose":120,"halted":0,"volume":178500,"delay":0,"changeRate":0.013333333333333286,"floatShares":54831344,"shares":54831344,"eps":2.951367,"marketStatus":"交易中","change":1.6,"latestTime":"09-08 14:30:30","open":127,"high":127,"low":115,"amount":21207350,"amplitude":0.1,"askPrice":122.3,"askSize":200,"bidPrice":121.6,"bidSize":1050,"shortable":0,"etf":0,"ttmEps":2.673,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1788855000000},"marketStatusCode":2,"adr":0,"listingDate":1777910400000,"exchange":"SEHK","adjPreClose":120,"openAndCloseTimeList":[[1788831000000,1788840000000],[1788843600000,1788854400000]],"volumeRatio":0.696232,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01609","defaultTab":"news","newsList":[{"id":"2665136179","title":"天星医疗(1609.HK)获调入港股通，9月7日起正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2665136179","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665136179?lang=zh_cn&edition=full","pubTime":"2026-09-06 17:00","pubTimestamp":1788685246,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1100","BK1148","01609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112350195","title":"天星医疗8月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1112350195","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112350195?lang=zh_cn&edition=full","pubTime":"2026-09-03 18:03","pubTimestamp":1788429806,"startTime":"0","endTime":"0","summary":"2026年9月3日，天星医疗披露截至2026年8月31日的证券变动月报表，显示公司报告期内未有新增发行或股份变动，股本结构保持稳定。截至8月31日，已发行股份和已发行股份总数均维持在54,831,344股，未出现库存股情况。本期内，公司未发生任何新股份发行、回购股份或库存股份变动，也无执行股份期权或股权激励计划的相关事项。根据公告，天星医疗承诺其所有发行及交易合规，严格遵循香港联交所《上市规则》及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662798974","title":"港股异动 | 天星医疗(01609)午后涨超7% 公司下月有望进入港股通 中报后官宣回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2662798974","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662798974?lang=zh_cn&edition=full","pubTime":"2026-08-26 14:37","pubTimestamp":1787726235,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，天星医疗午后涨超7%，截至发稿，涨7.07%，报149.9港元，成交额3001.51万港元。消息面上，天星医疗宣布，已获恒生指数有限公司选定并将被纳入恒生综合指数成份股，自9月7日起生效。被纳入恒生综合指数成份股后，公司股份预计将符合沪港通及深港通交易的纳入标准。公司同时宣布，拟回购不超过290万股H股，占公司已发行H股总数约5.29%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1148","BK4585","BK4588","BK1100","VXUS","KCAI","FLHK","01609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128322483","title":"天星医疗（01609）将于9月7日纳入恒生综合指数 有望进入沪深港通标的范围","url":"https://stock-news.laohu8.com/highlight/detail?id=1128322483","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128322483?lang=zh_cn&edition=full","pubTime":"2026-08-24 17:11","pubTimestamp":1787562670,"startTime":"0","endTime":"0","summary":"北京天星医疗股份有限公司8月24日发布自愿公告称，根据恒生指数有限公司于2026年8月21日公布的2026年第二季度恒生指数系列检讨结果，公司股票获选纳入恒生综合指数成份股，生效日期为2026年9月7日。公告指出，随本次纳入，天星医疗股份预计将符合沪港通及深港通交易的纳入标准。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661922423","title":"天星医疗(01609)：获选纳入恒生综合指数成份股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661922423","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661922423?lang=zh_cn&edition=full","pubTime":"2026-08-24 17:06","pubTimestamp":1787562414,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天星医疗(01609)发布公告，根据恒生指数有限公司于2026年8月21日公布的2026年第二季度恒生指数系列检讨结果，公司已获恒生指数有限公司选定并将被纳入恒生综合指数成份股，自2026年9月7日起生效。被纳入恒生综合指数成份股后，公司股份预计将符合沪港通及深港通交易的纳入标准。董事会认为，获选纳入恒生综合指数，是公司上市后资本市场建设的重要进展，有望进一步提升公司在香港资本市场的关注度和可投资性，扩大潜在投资者覆盖。公司将继续专注于运动医学领域的产品创新、临床价值创造及全球化业务发展，持续提升经营质量，为公司股东及投资者创造长期价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSCI","BK1148","BK1100","01609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660496499","title":"天星医疗上半年净利润下滑26%：系上市费用增加1900万元！上市首日股价曾大涨超118%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660496499","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660496499?lang=zh_cn&edition=full","pubTime":"2026-08-19 00:18","pubTimestamp":1787069884,"startTime":"0","endTime":"0","summary":"作为今年5月成功登陆港交所的运动医学企业北京天星医疗股份有限公司（天星医疗，HK01609，股价163港元，市值89.38亿港元），在上市初期曾迎来资本市场的强劲追捧，上市当天股价较发售价大涨超118%。然而，在上市后交出的首份半年度成绩单中，公司却出现了增收不增利的局面。8月17日，天星医疗发布了截至2026年6月30日止六个月的未经审计中期业绩公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608193844950051.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608193844950051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","01609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163624193","title":"天星医疗（01609）获批回购不超290万股H股　占已发行H股约5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163624193","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163624193?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:16","pubTimestamp":1787044589,"startTime":"0","endTime":"0","summary":"北京天星医疗股份有限公司8月18日发布自愿公告称，公司已获得股东批准授予董事会一般性回购授权，并计划在授权有效期内适时回购不超过290万股H股，占本公告日期已发行H股总数约5.29%。根据公告，回购授权于2026年6月26日举行的公司2025年年度股东会上获通过，可回购的H股上限为5,483,134股，约占授权当日已发行H股总数的10%。董事会现决定在该授权框架下执行本次股份回购计划。天星医疗董事会已授权董事长全权处理与H股回购相关的具体事宜。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660246585","title":"天星医疗(01609.HK)拟回购不超过290万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660246585","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660246585?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:15","pubTimestamp":1787044552,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1100","BK1148","01609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660450669","title":"港股异动 | 天星医疗(01609)再涨超7% 上半年海外收入增超七成 占比接近四分之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2660450669","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660450669?lang=zh_cn&edition=full","pubTime":"2026-08-18 15:40","pubTimestamp":1787038856,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，天星医疗(01609)再涨超7%，月内累计涨幅逾35%。截至发稿，涨3.25%，报159港元，成交额3052.47万港元。消息面上，天星医疗发布中期业绩，上半年实现收入约人民币1.63亿元，同比增长21.6%；经调整后的净利润约4889.7万元，同比增长24.3%，盈利增长主要得益于核心产品销量的大幅增长及有效的成本管控。值得注意的是，公司加快国际市场拓展战略，这一举措显著提升了海外市场覆盖率及业务规模。期内来源于海外的销售收入约为4069.8万元，较2025年同期增长70.6%。海外收入占总收入的比例提升至24.9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481296.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","BK4585","VXUS","BK4588","BK1148","KCAI","01609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660342481","title":"天星医疗(01609.HK)公布中期业绩 净利2740.2万元 同比减少26.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660342481","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660342481?lang=zh_cn&edition=full","pubTime":"2026-08-17 18:23","pubTimestamp":1786962191,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1100","BK1148","01609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134377412","title":"天星医疗(01609)披露2026年中期业绩：收入1.63亿元 同比增21.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1134377412","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134377412?lang=zh_cn&edition=full","pubTime":"2026-08-17 18:21","pubTimestamp":1786962103,"startTime":"0","endTime":"0","summary":"北京天星医疗股份有限公司8月17日公布截至2026年6月30日止六个月未经审计的中期业绩。报告期内，公司实现收入16,342.7万元，同比增长21.6%；毛利12,129.6万元，同比增长21.8%，毛利率由74.1%微升至74.2%。期内溢利为2,740.2万元，同比下降26.1%，主要受上市费用增加影响。若剔除股份奖励及上市开支，调整后期内溢利4,889.7万元，同比增长24.3%。报告期公司无重大收购或出售事项。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659116784","title":"港股异动 | 天星医疗(01609)盘中涨超12% 无线缆手持刨削系统获北京市首台（套）认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2659116784","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659116784?lang=zh_cn&edition=full","pubTime":"2026-08-14 15:23","pubTimestamp":1786692198,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，天星医疗盘中涨超12%，截至发稿，涨10.38%，报150港元，成交额1324.27万港元。公开资料显示，天星医疗是中国领先的运动医学整体解决方案提供商，专注于运动医学植入物、手术设备及相关耗材的研发、生产与商业化。根据灼识咨询数据，按2024年销售收入计，天星医疗为中国第四大、国产第一大运动医学植入物及器械供应商，市场份额6.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479971.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","01609","VXUS","BK1148","BK4588","BK4585","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188087233","title":"天星医疗（01609）拟于2026年8月17日审议2026年中期业绩及股息方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1188087233","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188087233?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:51","pubTimestamp":1785919906,"startTime":"0","endTime":"0","summary":"天星医疗（01609）8月5日公告称，公司董事会将于2026年8月17日（星期一）召开会议，主要议程包括：一、审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及相关公告；二、讨论并考虑建议派发2026年中期股息（如有）。本次会议决议结果及相关财务数据将在会后另行公布。\n公告显示，截至公告日，公司董事会由执行董事董文兴先生、和路先生；非执行董事张迪女士、常喜先生、王国瑋先生、易琳女士及周瑔先生；以及独立非执行董事吕振林先生、邓宇先生、刘宝杰先生及王春飞先生组成。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172698138","title":"天星医疗（01609）拟设立2026年度股份激励计划 总股份授予上限约548万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1172698138","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172698138?lang=zh_cn&edition=full","pubTime":"2026-08-03 20:45","pubTimestamp":1785761145,"startTime":"0","endTime":"0","summary":"2026年8月3日，天星医疗公告称，公司董事会已审议通过并建议采纳《2026年度股份激励计划》，并将于2026年第二次临时股东大会上提请股东审议该计划及相关授权事项。公司表示，将在适时向全体股东寄发载有股份激励计划详细条款及股东大会通知的通函。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656379796","title":"天星医疗(01609.HK)建议采纳2026年度股份激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2656379796","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656379796?lang=zh_cn&edition=full","pubTime":"2026-08-03 20:39","pubTimestamp":1785760740,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1148","BK1100","01609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184354460","title":"天星医疗7月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1184354460","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184354460?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:49","pubTimestamp":1785746992,"startTime":"0","endTime":"0","summary":"北京天星医疗股份有限公司于2026年8月3日发布了截至2026年7月31日的股份变动月报表。公告显示，公司法定注册股本维持人民币54,831,344元，面值每股人民币1元，已发行普通股股份数为54,831,344股，截至报告期末与上月保持一致。公司指出，截至本月底其公众持股量符合香港联交所相关规定。公告同时确认，天星医疗按照香港联交所《上市规则》及相关法律法规的要求履行信息披露及合规义务，所有证券发行及股份变动事项均获得董事会正式授权。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164516635","title":"天星医疗更新2026年6月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1164516635","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164516635?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:57","pubTimestamp":1783069075,"startTime":"0","endTime":"0","summary":"天星医疗于2026年7月3日发布2026年6月股份变动月报表。本次公告显示，截至2026年6月30日，公司法定注册股本共计约5,483.13万元，与上月持平，面值为人民币1元。报告期内，公司普通股H股的已发行股份与库藏股数量无变动。公告同时披露，在报告期内并无任何可转债、权证或其他发行协议发生变动，公司确认已遵守香港联交所《上市规则》及相关法律法规。本次月报由联合公司秘书梁晓丹正式签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647453054?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["00600","07666","02526","03310","01191","01081","06106","06675","01672","01779","03277","01866","09630","00068","BK4585","BK4588","03625","06872","03355","01286","09637","01651","00412","06656","00376","02616","02696","07688","01133","03887","02672","03388","01392","01440","02272","06938","07630","00863","02723","00340","02335","02670","02553","01236","02142","02729","02726","06658","01021","02632","01511","06636","01956","01609","00100","01879","03661"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1134629277","title":"天星医疗宣布不派2025年度股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1134629277","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134629277?lang=zh_cn&edition=full","pubTime":"2026-06-26 20:06","pubTimestamp":1782475583,"startTime":"0","endTime":"0","summary":"天星医疗(01609)于6月26日举行年度股东会，审议通过了2025年度利润分配方案。根据决议，公司截至2025年12月31日止年度将不进行利润分配，意味着股东无法获得当期股息。\n此次股东会还审议了董事会工作报告、财务决算报告、续聘审计机构等多项议案，并批准撤销监事会、修订公司章程及议事规则等特别决议案。前述议案均获高比例赞成票通过，其中涉及不派息的利润分配方案以100%赞成票批准。\n公司未披露不派息的具体原因，投资者需留意后续盈利及派息政策变化。天星医疗主要从事运动医学相关业务，此前未有公开的派息记录。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"天星医疗宣布不派2025年度股息","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173127576","title":"天星医疗宣布不派2025年度股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1173127576","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173127576?lang=zh_cn&edition=full","pubTime":"2026-06-05 17:22","pubTimestamp":1780651325,"startTime":"0","endTime":"0","summary":"天星医疗(01609)发布公告，董事会不建议就截至2025年12月31日止年度派发股息，即2025年度将不进行任何股息分派。该事项尚需提交年度股东会审议。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"天星医疗宣布不派2025年度股息","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01609"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.starsportmed.com/","stockEarnings":[{"period":"1week","weight":-0.2258},{"period":"1month","weight":-0.0755},{"period":"3month","weight":-0.376},{"period":"6month","weight":0.2183},{"period":"ytd","weight":0.2183}],"compareEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0345},{"period":"6month","weight":-0.0188},{"period":"1year","weight":-0.0002},{"period":"ytd","weight":-0.0085}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"北京天星医疗股份有限公司(简称“天星医疗”)作为国产运动医学的领导者,致力于提供运动医学的整体临床解决方案,公司坐落于北京经济技术开发区,注册资本4000多万,现有员工200余人。应用于肩关节、膝关节、足/踝关节、髋关节、肘关节、手/腕关节的运动医学设备、植入物和手术器械共计300多个品规通过NMPA的批准,临床应用于国内31个省市、自治区的数千家医院。主要从事运动医学植入物、有源设备及耗材,以及手术工具的研发、生产与销售。","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.121197},{"month":2,"riseRate":0.5,"avgChangeRate":0.06192},{"month":3,"riseRate":0.428571,"avgChangeRate":0.034993},{"month":4,"riseRate":0.5,"avgChangeRate":-0.011524},{"month":5,"riseRate":0.5,"avgChangeRate":0.066004},{"month":6,"riseRate":0.2,"avgChangeRate":-0.212662},{"month":7,"riseRate":0.4,"avgChangeRate":0.059988},{"month":8,"riseRate":0.4,"avgChangeRate":0.05496},{"month":9,"riseRate":0.4,"avgChangeRate":-0.011761},{"month":10,"riseRate":0.4,"avgChangeRate":-0.000213},{"month":11,"riseRate":0.333333,"avgChangeRate":0.179457},{"month":12,"riseRate":0.5,"avgChangeRate":0.080552}],"exchange":"SEHK","name":"天星医疗","nameEN":"STAR SPORTS MED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天星医疗(01609)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天星医疗(01609)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天星医疗,01609,天星医疗股票,天星医疗股票老虎,天星医疗股票老虎国际,天星医疗行情,天星医疗股票行情,天星医疗股价,天星医疗股市,天星医疗股票价格,天星医疗股票交易,天星医疗股票购买,天星医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天星医疗(01609)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天星医疗(01609)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}